NSE - SMEListed
Remus Pharmaceuticals Limited
Company websiteInvestor note: Remus Pharmaceuticals Limited aims to raise ₹3,88,000 crore. The fresh issue of ₹3,88,000 crore goes to the company while the OFS of ₹0 crore is an existing-shareholder sale.
Subscription window: 17-05-2023 to 19-05-2023. Allotment and listing timelines: 24-05-2023 / 29-05-2023. Tip: check promoter holding and recent financials before applying.
Start Date17-05-2023
End Date19-05-2023
Listing Date29-05-2023
Allotment Date24-05-2023
Current Price₹1,711.25
GMP₹470 (38.24%)
Lot Size100 Shares
Subscription61.53 Times
Face Value₹10 per share
Listing atNSE
Issue Price₹1150 - ₹1229
Pre Issue₹10,85,000
Post Issue₹14,73,000
Issue Size₹3,88,000
(aggregating up to 47.69 Cr)
(aggregating up to 47.69 Cr)
Fresh Issue₹3,88,000
(aggregating up to 47.69 Cr)
(aggregating up to 47.69 Cr)
Offer For Sale-
The Grey Market Premium (GMP) for Remus Pharmaceuticals Limited is currently around ₹470 (38.24%). This indicates an estimated listing price of approximately ₹1,620 based on the latest market sentiment. Please note that GMP values are unofficial and can change frequently as they depend on demand, market conditions, and investor activity.
Gmp Details
| Last Updated | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
11 Nov 2025, 10:19 | ₹1,229 | ₹470 | ₹1,699 (38.24%) |
21 Mar 2025, 06:55 | ₹1,229 | ₹470 | ₹1,699 (38.24%) |
Financials overview In Lakhs
Here is a quick look at the recent financial performance of Remus Pharmaceuticals Limited . The numbers below ( In Lakhs ) show how the company’s revenue and profits have changed over the last few years. This helps investors understand how strongly the business is growing and how stable its financial health is before applying for the IPO.
Key Performance
| KPI | Values |
|---|---|
EPS | 33.86 |
ROE | 71.44 |
ROCE | 69.99 |
RONW | 52.64 |
PRE IPO(PE) | 21.09 |
POST IPO(PE) | 0 |
Subscription Demand (in ₹ Crore)
| Category | Offered | Demand | Times |
|---|---|---|---|
QIBs | ₹9.06 | 183.37 | 20.24 |
RETAIL | ₹15.85 | 594.54 | 37.51 |
Total | ₹24.91 | 777.91 | 31.23 |
The IPO reservation for Remus Pharmaceuticals Limited shows how the total issue is divided among different investor categories. This includes allocations for Retail Investors, Qualified Institutional Buyers (QIBs), and Non-Institutional Investors (NIIs). Understanding the reservation structure helps investors know how much of the issue is set aside for their category before applying.
IPO Reservation
| Category | Shares Offers | No. of Shares |
|---|---|---|
Retail | 33.25% | 1,29,000 |
NII(HNI) | 14.25% | 55,300 |
QIB | 47.47% | 1,84,200 |
Market Maker | 5.03% | 19,500 |
TOTAL | 100.00% | 3,88,000 |
Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
Retail (Min) | 1 | 100 | ₹1,22,900 | |
HNI | 2 | 200 | ₹2,45,800 |
Below you can find the official contact details of Remus Pharmaceuticals Limited along with the registrar handling the IPO process. This information helps investors reach out for queries related to the company or for checking the allotment status and application updates once the IPO process begins.
Company Details
Email: cs@remuspharma.com
Phone: +079- 2999 9857
Website: http://www.remuspharma.com/
Address: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli bopal Road, Ahmedabad - 380054